Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting

References

• globocan.iarc.fr [homepage on the Internet]GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012World Health Organization2012 [updated 2017; cited July 13, 2016]. Available from: http://globocan.iarc.fr/Default.aspxAccessed August 29, 2017
   Google Scholar
• cancer.org [homepage on the Internet]Cancer Facts & Figures 2017American Cancer Society2017 [updated 2017; cited February 8, 2017]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.htmlAccessed August 29, 2017
   Google Scholar
• cancer.org [homepage on the Internet]Non-small cell lung cancerAmerican Cancer Society2017 [updated 2017; cited February 10, 2017]. Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer.htmlAccessed August 29, 2017
   Google Scholar
• BrahmerJHornLJackmanDFive-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): clinical characteristics of long-term survivors [abstract]Cancer Res20177713 SupplCT077
   Web of Science ®Google Scholar
• CetinKEttingerDSHeiYJO’MalleyCDSurvival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results ProgramClin Epidemiol2011313914821607015
   PubMedGoogle Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V8.2017National Comprehensive Cancer Network2017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed August 29, 2017
   Google Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• Keytruda® (pembrolizumab) [package insert]Whitehouse Station, NJMerck & Co Inc2017
   Google Scholar
• NovelloSBarlesiFCalifanoRMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol201230172055206222547591
   PubMed Web of Science ®Google Scholar
• SocinskiMAOkamotoIHonJKSafety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancerAnn Oncol20132492390239623842283
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• seer.cancer.gov [homepage on the Internet]SEER Cancer Stat Facts: lung and bronchus cancer Surveillance, Epidemiology, and End Results ProgramNational Cancer Institute2014 [updated June 28, 2017; cited Jul 25, 2017]. Available from: http://seer.cancer.gov/statfacts/html/lungb.htmlAccessed August 29, 2017
   Google Scholar
• GajraADefining the issues in the treatment of elderly patients with advanced non-small-cell lung cancerLung Cancer Management2015411730
   Google Scholar
• Abraxane® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [package insert]Summit, NJCelgene Corporation2015
   Google Scholar
• Gemzar (gemcitabine) [package insert]Indianapolis, INEli Lilly and Company2017
   Google Scholar
• WangXSLuCShiQSymptom burden and survival outcome: 3 cycles versus 6 cycles of chemotherapy in advanced NSCLC [abstract]J Clin Oncol20072518 Suppl17054
   Google Scholar
• SoonYYStocklerMRAskieLMBoyerMJDuration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trialsJ Clin Oncol200927203277328319470938
   PubMed Web of Science ®Google Scholar
• SculierJPMoro-SibilotDFirst- and second-line therapy for advanced nonsmall cell lung cancerEur Respir J200933491593019336594
   PubMed Web of Science ®Google Scholar
• De MarinisFDe SantisSDe PetrisLSecond-line chemotherapy for non-small cell lung cancerAnn Oncol200617Suppl 5v68v7116807467
   PubMed Web of Science ®Google Scholar
• Keytruda® (pembrolizumab) [package insert]Whitehouse Station, NJMerck & Co Inc2015
   Google Scholar
• Opdivo® (nivolumab) [package insert]Princeton, NJBristol-Myers Squibb Company2015
   Google Scholar
• Tecentriq® (atezolizumab) [package insert]South San Francisco, CAGenentech, Inc2016
   Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BarlesiFParkKCiardielloFPrimary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC [abstract]Ann Oncol201627Suppl 6LBA44_PR
   Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA expands approved use of Opdivo to treat lung cancer [press release]Silver Spring, MDUS Food and Drug Administration2015 [March 5]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436534.htmAccessed August 29, 2017
   Google Scholar
• US Food and Drug AdministrationFDA approves Keytruda for advanced non-small cell lung cancer [press release]Silver Spring, MDUS Food and Drug Administration2015105 Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htmAccessed August 29, 2017
   Google Scholar
• fda.gov [homepage on the Internet]Atezolizumab (TECENTRIQ)US Food and Drug Administration2016 [updated October 19, 2016; cited November 30, 2016]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm2016Accessed August 29, 2017
   Google Scholar